Bristol Total Stockholder Equity from 2010 to 2025

BMY Stock  USD 57.88  2.05  3.67%   
Bristol Myers Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity will likely drop to about 15.1 B in 2025. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
1987-12-31
Previous Quarter
17.1 B
Current Value
16.3 B
Quarterly Volatility
9.8 B
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 2 B or Selling General Administrative of 8.8 B, as well as many indicators such as Price To Sales Ratio of 2.95, Dividend Yield of 0.0274 or PTB Ratio of 6.94. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Bristol Myers Squibb over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Bristol Myers' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Bristol Total Stockholder Equity Regression Statistics

Arithmetic Mean21,114,136,020
Geometric Mean18,158,249,925
Coefficient Of Variation58.52
Mean Deviation10,035,789,988
Median15,956,000,000
Standard Deviation12,356,209,256
Sample Variance152675907.2T
Range46.8B
R-Value0.48
Mean Square Error125561593.3T
R-Squared0.23
Significance0.06
Slope1,251,206,830
Total Sum of Squares2290138607.6T

Bristol Total Stockholder Equity History

202515.1 B
202416.3 B
202329.4 B
202231.1 B
202135.9 B
202037.8 B
201951.6 B

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity16.3 B15.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.